Clinical Trials | September 11, 2024
Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS patients experience neuroinflammation and rapid neurodegeneration
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Effective, holistic, science-backed targeted solutions for symptomatic treatment
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Subscribe To Our Newsletter & Stay Updated
